Author

Nitin Gupta

Weizmann Institute of Science

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell-cell communication· 2 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

Suvendu GiriiD· 4 shared Alessandro GennaiD· 3 shared Arturo Simoni NievesiD· 3 shared Eytan RuppiniD· 3 shared Moshit LindzeniD· 3 shared Rishita ChatterjeeiD· 3 shared Arunachalam SekariD· 2 shared Boobash-Raj Selvadurai· 2 shared

Activity by Year

2025-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Suvendu GiriORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21

Suvendu Giri, Boobash-Raj Selvadurai, Arturo Simoni Nieves, Nitin Gupta, Moshit Lindzen, Rishita Chatterjee, Alessandro Genna, Marieke Van Daele, Deepthi Ramesh-Kumar, Mirie Zerbib, Roni Oren, Isabelle Sophie Meijer, Elisabeth Franziska Wippich, Yahel Avraham, Rony Dahan, , Yosef Yarden

This study develops a bispecific antibody targeting MERTK and EGFR to overcome drug resistance in lung cancer with mutations in exons 19, 20, and 21.

bioRxiv · Oct 16, 2025 · PreprintCancer Biology

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

Rishita Chatterjee, Arturo Simoni Nieves, An Nhien Truong, Moshit Lindzen, Furkan Ozmen, Christopher Cherry, Pascale Zwicky, Saptaparna Mukherjee, Boobash-Raj Selvadurai, Tomer Meir Salame, Nitin Gupta, Suvendu Giri, Lior Kramarski, Yahel Avraham, Eviatar Weizman, , Yosef Yarden

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

bioRxiv · Jun 23, 2025 · PreprintCancer Biology

Inducible re-epithelialization of cancer cells increases autophagy and DNA damage: implications for breast cancer dormancy

Diana Drago Garcia, Suvendu Giri, Rishita Chattaerjee, Arturo Simoni Nieves, Maha Abedrabbo, Alessandro Genna, Mary Luz Uribe Rios, Moshit Lindzen, Arunachalam Sekar, Nitin Gupta, Noa Aharoni, Tithi Bhandari, Agalyan Mayalagu, Luisa E. Schwarzmüller, Nooraldeen Tarade, , Yosef Yarden

The paper shows that inducing epithelial traits in breast cancer cells increases autophagy and DNA damage, potentially contributing to tumor dormancy and reactivation.

bioRxiv · Feb 9, 2025 · PreprintCancer Biology

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications

Arunachalam Sekar, Rishita Chatterjee, Boobash Raj Selvadurai, Lipika R. Pal, Aakanksha Verma, Nishanth Belugali Nataraj, Diana Drago Garcia, Suvendu Giri, Alessandro Genna, Feride Karatekin, Nitin Gupta, Mirie Zerbib, Yaron Vinik, Tamir Avioz, Eviatar Weizman, , Yosef Yarden

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.

bioRxiv · Jan 17, 2025 · PreprintCancer Biology